CG Oncology (CGON) FCF Margin (2023 - 2026)
CG Oncology's (CGON) quarterly FCF Margin came in at 5281.99% in Q1 2026, up 5105070.0% YoY from N/an in Q1 2025, and down 238.74% on a QoQ basis from 1559.3% in Q4 2025.
Powered by 
Analysis
CG Oncology (CGON) FCF Margin (2023 - 2026) Analysis & Trends
CG Oncology (CGON) has 4 years of FCF Margin data on file, last reported at 5281.99% in Q1 2026.
- Quarterly FCF Margin rose 5105070.0% year-over-year to 5281.99% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 3162.0% (up 925734.0% YoY) and the FY2025 annual result came in at 3278.07%, up 365319.0% from the prior year.
- FCF Margin declined to 5281.99% in Q1 2026, from 1559.3% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 1559.3% in Q4 2025 to a low of 1464500.0% in Q4 2023.
- A 4-year average of 157402.16% and a median of 5281.99% in 2026 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2024 — FCF Margin surged 145992303 bps — and 2025, when it plunged 5141322 bps.
- Tracing CGON's FCF Margin over 4 years: stood at 1464500.0% in 2023, then jumped by 100 bps to 4576.97% in 2024, then soared by 66 bps to 1559.3% in 2025, then slumped by 239 bps to 5281.99% in 2026.
- The last three FCF Margin figures came in at 5281.99% (Q1 2026), 1559.3% (Q4 2025), and 2338.6% (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.27 Bn | 131.42 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 63.45 Bn | 58.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.73 Bn | 52.59 Bn | 52.00 Mn | -388.28% |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 25.68% |
| 7 | Alnylam Pharmaceuticals | 35.14 Bn | 31.84 Bn | 992.69 Mn | 22.62% |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 70.82% |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | -22.35% |
| 10 | CG Oncology | 6.55 Bn | 6.55 Bn | -2.77 Mn | -4,055.75% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -4,055.75% |
| Mar 31, 2026 | -5,285.96% |
| Dec 31, 2025 | -1,559.99% |
| Sep 30, 2025 | -2,340.40% |
| Mar 31, 2025 | -56,332.69% |
| Dec 31, 2024 | -4,576.97% |
| Sep 30, 2024 | -37,018.60% |
| Jun 30, 2024 | -14,535.14% |
| Mar 31, 2024 | -4,919.47% |
| Dec 31, 2023 | -1,464,500.00% |
| Sep 30, 2023 | -136,244.44% |
| Mar 31, 2023 | -4,116.49% |